Processa Pharmaceuticals (PCSA) Non-Current Assets (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Non-Current Assets came in at $2.6 million in Q1 2026, up 4747.89% YoY from $53272.0 in Q1 2025, and up 20.53% on a QoQ basis from $2.1 million in Q4 2025.
Processa Pharmaceuticals (PCSA) Non-Current Assets (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 14 years of Non-Current Assets data on file, last reported at $2.6 million in Q1 2026.
- Quarterly Non-Current Assets rose 4747.89% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.9 million (up 10972.12% YoY) and the FY2025 annual result came in at $2.1 million, up 2711.49% from the prior year.
- Non-Current Assets advanced to $2.6 million in Q1 2026, from $2.1 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $7.9 million in Q1 2022 to a low of $29853.0 in Q2 2025.
- A 5-year average of $1.8 million and a median of $193140.0 in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets slumped 97.73% — and 2026, when it jumped 4747.89%.
- Tracing PCSA's Non-Current Assets over 5 years: stood at $233122.0 in 2022, then plunged by 34.97% to $151592.0 in 2023, then sank by 49.73% to $76212.0 in 2024, then surged by 2711.49% to $2.1 million in 2025, then gained by 20.53% to $2.6 million in 2026.
- The last three Non-Current Assets figures came in at $2.6 million (Q1 2026), $2.1 million (Q4 2025), and $997814.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - | 3,210.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.58 Mn |
| Dec 31, 2025 | 2.14 Mn |
| Sep 30, 2025 | 997,814.00 |
| Jun 30, 2025 | 29,853.00 |
| Mar 31, 2025 | 53,272.00 |
| Dec 31, 2024 | 76,212.00 |
| Sep 30, 2024 | 98,696.00 |
| Jun 30, 2024 | 120,726.00 |
| Mar 31, 2024 | 142,024.00 |
| Dec 31, 2023 | 151,592.00 |
| Sep 30, 2023 | 175,264.00 |
| Jun 30, 2023 | 193,140.00 |
| Mar 31, 2023 | 213,322.00 |
| Dec 31, 2022 | 233,122.00 |
| Sep 30, 2022 | 7.72 Mn |
| Jun 30, 2022 | 7.70 Mn |
| Mar 31, 2022 | 7.92 Mn |
| Dec 31, 2021 | 8.14 Mn |
| Sep 30, 2021 | 8.36 Mn |
| Jun 30, 2021 | 8.57 Mn |